AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.3 |
Market Cap | 219.48M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.95 |
PE Ratio (ttm) | -3.47 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.54 |
Volume | 801,670 |
Avg. Volume (20D) | 2,113,286 |
Open | 3.54 |
Previous Close | 3.47 |
Day's Range | 3.28 - 3.57 |
52-Week Range | 1.44 - 6.42 |
Beta | undefined |
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...
Analyst Forecast
According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 203.08% from the latest price.
Next Earnings Release
Analysts project revenue of $73.00K, reflecting a -53.21% YoY shrinking and earnings per share of -0.26, making a 23.81% increase YoY.
1 month ago · seekingalpha.com
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im...